Revvity, Inc. (RVTY) is a leading global health sciences company with a market capitalization of $11.4 billion. The company offers a wide range of advanced instruments, reagents, software, and services to support diagnostics, genomics, drug discovery, and life sciences research.
Despite its strong presence in the industry, shares of Revvity have underperformed the broader market over the past 52 weeks. RVTY stock has seen a decline of 12.5% during this period, while the S&P 500 Index has gained nearly 13%. However, on a year-to-date basis, the company has shown resilience with a 3.7% increase in its stock price, outpacing the marginal return of the SPX.
When compared to the State Street Health Care Select Sector SPDR ETF (XLV), Revvity’s shares have lagged behind, with XLV showing a 6.5% increase over the past 52 weeks.
Revvity recently reported robust Q4 2025 results, with revenue reaching $772 million and adjusted EPS of $1.70. The company’s performance was primarily driven by strong growth in Diagnostics, with fourth-quarter revenue of $390 million, reflecting a 10% reported growth and 7% organic growth. Additionally, Revvity provided upbeat full-year 2026 guidance, projecting revenue in the range of $2.96 billion to $2.99 billion, 2% to 3% organic growth, and adjusted EPS of $5.35 to $5.45. Despite these positive results, the stock experienced a 1.6% decline on the day of the earnings announcement.
Analysts forecast that RVTY’s adjusted EPS for the fiscal year ending in December 2026 will grow by 6.9% year-over-year to $5.41. The company has a strong earnings surprise history, consistently beating consensus estimates in the past four quarters.
Of the 18 analysts covering Revvity, the consensus rating is a “Moderate Buy,” with eight “Strong Buy” ratings, one “Moderate Buy,” and nine “Hold” ratings.
Baird analyst Catherine Ramsey Schulte recently raised the price target on Revvity to $129 while maintaining an “Outperform” rating. The mean price target of $119.40 represents a 19% premium to RVTY’s current price levels, with the Street-high price target of $140 suggesting a 39.5% potential upside.
In conclusion, Revvity continues to demonstrate its strength in the health sciences industry, with promising financial results and optimistic analyst ratings. Investors may want to keep an eye on this company as it navigates through the evolving landscape of healthcare and life sciences research.
Please note that the information provided in this article is for informational purposes only and does not constitute investment advice. It was originally published on Barchart.com.
